USSTOCK.TODAY
Market Closed
Log in Sign up

Lunit and Summit Therapeutics Sign Research Agreement to Utilize AI Pathology Platform

Pharmaceutical Technology · ·by G4L

SMMT
SMMT Summit Therapeutics Inc
$10.67 -9.73%
View chart & analysis →
  1. 1Lunit and Summit Therapeutics have signed a research agreement to analyze the tumor microenvironment using the AI pathology platform Lunit SCOPE IO.
  2. 2ivonescimab has been administered to more than 5,000 clinical trial participants worldwide and more than 100,000 commercial patients in China.
  3. 3There are a total of 17 Phase 3 clinical studies that have been announced, are ongoing, or have been completed regarding ivonescimab.

So what's the key point?

Lunit has decided to conduct research to analyze the environment surrounding cancer cells using artificial intelligence technology. This collaboration is related to a drug that has 17 clinical studies in progress.

Source Pharmaceutical Technology · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →